297 related articles for article (PubMed ID: 16160169)
1. Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.
Mishin VP; Novikov D; Hayden FG; Gubareva LV
J Virol; 2005 Oct; 79(19):12416-24. PubMed ID: 16160169
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
4. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI; Barclay WS; Zambon MC
J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
8. Position statement: global neuraminidase inhibitor susceptibility network.
Zambon M; Hayden FG;
Antiviral Res; 2001 Mar; 49(3):147-56. PubMed ID: 11428241
[No Abstract] [Full Text] [Related]
9. Neuraminidase inhibitors as antiviral agents.
Alymova IV; Taylor G; Portner A
Curr Drug Targets Infect Disord; 2005 Dec; 5(4):401-9. PubMed ID: 16535861
[TBL] [Abstract][Full Text] [Related]
10. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
Blick TJ; Sahasrabudhe A; McDonald M; Owens IJ; Morley PJ; Fenton RJ; McKimm-Breschkin JL
Virology; 1998 Jun; 246(1):95-103. PubMed ID: 9656997
[TBL] [Abstract][Full Text] [Related]
11. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the role of neuraminidase in the receptor-binding activity of influenza B virus: the inhibitory effect of Zanamivir on haemadsorption.
Luo C; Nobusawa E; Nakajima K
J Gen Virol; 1999 Nov; 80 ( Pt 11)():2969-2976. PubMed ID: 10580059
[TBL] [Abstract][Full Text] [Related]
13. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Govorkova EA; Fang HB; Tan M; Webster RG
Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus neuraminidase inhibitors.
Gubareva LV; Kaiser L; Hayden FG
Lancet; 2000 Mar; 355(9206):827-35. PubMed ID: 10711940
[TBL] [Abstract][Full Text] [Related]
15. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Yen HL; Herlocher LM; Hoffmann E; Matrosovich MN; Monto AS; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4075-84. PubMed ID: 16189083
[TBL] [Abstract][Full Text] [Related]
16. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
Sauerbrei A; Haertl A; Brandstaedt A; Schmidtke M; Wutzler P
Med Microbiol Immunol; 2006 Jun; 195(2):65-71. PubMed ID: 16059699
[TBL] [Abstract][Full Text] [Related]
17. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.
Greengard O; Poltoratskaia N; Leikina E; Zimmerberg J; Moscona A
J Virol; 2000 Dec; 74(23):11108-14. PubMed ID: 11070006
[TBL] [Abstract][Full Text] [Related]
18. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
19. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
[TBL] [Abstract][Full Text] [Related]
20. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
Barnett JM; Cadman A; Gor D; Dempsey M; Walters M; Candlin A; Tisdale M; Morley PJ; Owens IJ; Fenton RJ; Lewis AP; Claas EC; Rimmelzwaan GF; De Groot R; Osterhaus AD
Antimicrob Agents Chemother; 2000 Jan; 44(1):78-87. PubMed ID: 10602727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
